Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2522-8307
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients ; volume:43 ; number:1 ; day:10 ; month:12 ; year:2019 ; pages:1-6 ; date:12.2019
Bulletin of the National Research Centre / al- Markaz al-Qaumī li-'l-Buḥūṭ; 43, Heft 1 (10.12.2019), 1-6, 12.2019
- Urheber
-
Nemr, Nader
Mandour, Mohamed
Badran, Dahlia
Kishk, Rania
Attia, Fawzy
Hashish, Abdullah
Gaber, Ahmed
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s42269-019-0226-3
- URN
-
urn:nbn:de:101:1-2020040500313567977730
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nemr, Nader
- Mandour, Mohamed
- Badran, Dahlia
- Kishk, Rania
- Attia, Fawzy
- Hashish, Abdullah
- Gaber, Ahmed
- SpringerLink (Online service)
Ähnliche Objekte (12)
Der 4G/5G-PAI-1-Polymorphismus beim primären Mammakarzinom
P2.03 The Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphism Affects Central Arterial Blood Pressure in Women
Die Bedeutung des 4G/5G-PAI-1-Promotorpolymorphismus beim Ovarialkarzinom
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Der 4G/5G-PAI-1-Polymorphismus beim primären Mammakarzinom
P2.03 The Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphism Affects Central Arterial Blood Pressure in Women
Die Bedeutung des 4G/5G-PAI-1-Promotorpolymorphismus beim Ovarialkarzinom
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Der 4G/5G-PAI-1-Polymorphismus beim primären Mammakarzinom
P2.03 The Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphism Affects Central Arterial Blood Pressure in Women
Die Bedeutung des 4G/5G-PAI-1-Promotorpolymorphismus beim Ovarialkarzinom
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease